Richard Scartozzi MD , FACS, FICS, FAAO, FAPCR, CPI

Ophthalmology•Danbury, CT

Retinal Disease

Dr. Richard Scartozzi, MD, FACS, FICS, FAAO, FAPCR, CPI, specializes in diseases and surgery of the retina, macula, and vitreous as a Vitreoretinal Surgeon, Partner, and Principal Investigator at Connecticut Eye Consultants

Join to View Full Profile

69 Sand Pit RdDanbury, CT 06810
Phone+1 203-791-2020
Fax+1 203-778-6238

Summary

Doctor Richard Scartozzi, MD, FACS, FICS, FAAO, FAPCR, CPI, is a clinician/surgeon, teacher, and researcher with years of experience. He has trained at top institutions such as Johns Hopkins Medical School, Wills Eye Hospital, and Doheny Eye Institute. Doctor Scartozzi is a Connecticut retina and macula specialist with a national reputation, skilled in the treatment of macular degeneration, macular holes and puckers, diabetic retinopathy, retinal detachments and tears, floaters, retinal vein occlusions, complications of cataract surgery, uveitis, sutureless small gauge vitrectomy surgery, eye laser surgery, and the use of Eylea, Vabysmo, Lucentis, Avastin, Ozurdex, Jetrea, macular eye vitamins, and other eye therapies.

Education & Training

University of Southern California/LAC+USC Medical CenterFellowship, Surgical Retina and Vitreous, 2006 - 2008
Sidney Kimmel Medical College at Thomas Jefferson University/Wills Eye HospitalResidency, Ophthalmology, 2003 - 2006
Zucker School of Medicine at Hofstra/NorthwellInternship, Internal Medicine, 2002 - 2003
Johns Hopkins University School of MedicineClass of 2002, M.D., Class Rank: 14 of 114
SUNY at Stony BrookB.S., Biochemistry, Valedictorian, 1994 - 1998

Certifications & Licensure

CA State Medical License 2006 - Present
NY State Medical License 2008 - 2026
CT State Medical License 2007 - 2025
PA State Medical License 2003 - 2006
American Board of Ophthalmology Ophthalmology
Association of Clinical Research ProfessionalsCertified Principal Investigator

Awards, Honors, & Recognition

Fellow (FAPCR) Academy of Physicians in Clinical Research, 2016
Certified Principal Investigator (CPI) Association of Clinical Research Professionals, 2014
Fellow (FICS) International College of Surgeons, 2014
Top Doctors: New York Metro Area Castle Connolly, 2014
Top Doctor Award Castle Connolly, 2013
Top Doctor Award International Association of Ophthalmologists, 2013
CMS Meaningful Use Stage 1 Certification NextGen Ambulatory EHR, NextGen Healthcare, 2012
Fellow (FACS) American College of Surgeons
Fellow (FAAO) American Academy of Ophthalmology
Join now to see all

Clinical Trials

Comparative Effectiveness Study of Intravitreal Aflibercept, Bevacizumab, and Ranibizumab for Diabetic Macular Edema Start of enrollment: 2012 Aug 01
Completed
Phase 3
Efficacy and Safety of RTH258 Versus Aflibercept - Study 1 Start of enrollment: 2014 Dec 08
COMPLETED
PHASE3
Study of Pegcetacoplan (APL-2) Therapy in Patients With Geographic Atrophy Start of enrollment: 2015 Sep 24
Completed
Phase 2
CLG561 Proof-of-Concept Study as a Monotherapy and in Combination With LFG316 in Subjects With Geographic Atrophy (GA) Start of enrollment: 2015 Sep 25
Completed
Phase 2
Study of Efficacy and Safety of Brolucizumab vs. Aflibercept in Patients With Visual Impairment Due to Diabetic Macular Edema Start of enrollment: 2018 Jul 23
Completed
Phase 3
Study to Compare the Efficacy and Safety of Intravitreal APL-2 Therapy With Sham Injections in Patients With Geographic Atrophy (GA) Secondary to Age-Related Macular Degeneration Start of enrollment: 2018 Aug 31
Completed
Phase 3
A Phase 3 Safety and Efficacy Study of Intravitreal Administration of Zimura (Complement C5 Inhibitor) Start of enrollment: 2020 Jun 22
COMPLETED
PHASE3
A Study to Evaluate the Efficacy, Durability, and Safety of KSI-301 Compared to Aflibercept in Patients With Macular Edema Due to Retinal Vein Occlusion (RVO) Start of enrollment: 2020 Sep 25
COMPLETED
PHASE3
A Trial to Evaluate the Efficacy, Durability, and Safety of KSI-301 Compared to Aflibercept in Participants With Diabetic Macular Edema (DME) Start of enrollment: 2020 Sep 30
TERMINATED
PHASE3
OPT-302 With Aflibercept in Neovascular Age-related Macular Degeneration (nAMD) Start of enrollment: 2021 Mar 12
Active, not recruiting
Phase 3
A Study to Evaluate the Efficacy and Safety of Intravitreal KSI-301 Compared With Intravitreal Aflibercept in Participants With Neovascular (Wet) Age-related Macular Degeneration (wAMD) Start of enrollment: 2021 Jun 23
COMPLETED
PHASE3
A Study to Evaluate the Efficacy and Safety of Intravitreal KSI-301 in Non-proliferative Diabetic Retinopathy (NPDR) Start of enrollment: 2021 Sep 07
TERMINATED
PHASE3
Join now to see all

Publications & Presentations

PubMed

4 citations
Postoperative endophthalmitis caused by Candida parapsilosis: clinical features and treatment outcomes.
Richard Scartozzi, D. Tom, Peter E. Liggett, Harry W. Flynn
Ophthalmic Surgery, Lasers & Imaging. 2011-03-10
12 citations
Bilateral improvement of persistent diffuse diabetic macular oedema after unilateral intravitreal bevacizumab (Avastin) injection.
R Scartozzi, J R Chao, A. C. Walsh, Dean Eliott
Eye. 2009-05-01
1 citations
Rhegmatogenous retinal detachment after a lower extremity dog bite: a case report
Tarek Alasil, Sam Eljammal, Richard Scartozzi, Dean Eliott
Cases Journal. 2008-10-07

Professional Memberships

American Academy of Ophthalmology - AAO
Fellow
American Society of Retina Specialists - ASRS
Member
International College of Surgeons - ICS
Fellow
American College of Surgeons - ACS
Fellow
New England Ophthalmological Society
Member
Academy of Physicians in Clinical Research - APCR
Fellow
Connecticut Society of Eye Physicians
Member
Vit-Buckle Society
Member

Other Languages

Italian

External Links

Practicehttp://www.cteye2020.com/
Professionalhttp://www.drscartozzi.com